Literature DB >> 11127395

Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice.

A Borgmann1, C Baldy, A von Stackelberg, B Beyermann, I Fichtner, P Nürnberg, G Henze.   

Abstract

For children with an early bone marrow relapse or relapsed T-cell acute lymphoblastic leukemia (ALL), allogeneic bone marrow transplantation (BMT) is currently the only therapeutic option with a curative approach. Here, the graft versus leukemia (GvL) effect seems to play an important role for long-term immunological control of leukemia. If a bone marrow donor is not available, autologous stem cell transplantation after high-dose chemotherapy has been used as an alternative option. The objective of this work was the induction of tumor specific cytotoxic T-lymphocytes (CTL) against autologous leukemic cells in order to generate the missing GvL effect after autoBMT. The first step was the establishment of an optimized and reliable mouse model. The second step was the induction of a GvL effect in an allogeneic approach to serve as a basis for further GvL experiments in an autologous approach in this mouse model. Leukemic cells from 11 out of 16 different pediatric patients were successfully established in mice and in one case passaged over 19 generations without changes of genotype or phenotype. The antileukemic activity of allogeneic human MNC as a GvL reaction and an accompanying GvHD in the mouse model was shown. Xenotransplanted ALL can be considered a clinically relevant model mimicking the human conditions and as a useful preclinical tool for the evaluation of novel immuno- or genetherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127395     DOI: 10.1080/08880010050211349

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  16 in total

1.  Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11).

Authors:  Susan J Zunino; David H Storms; Jonathan M Ducore
Journal:  Cancer Lett       Date:  2010-04-09       Impact factor: 8.679

2.  Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

Authors:  David M Barrett; Alix E Seif; Carmine Carpenito; David T Teachey; Jonathan D Fish; Carl H June; Stephan A Grupp; Gregor S D Reid
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

3.  The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.

Authors:  David T Teachey; Dana A Obzut; Jonathan Cooperman; Junjie Fang; Martin Carroll; John K Choi; Peter J Houghton; Valerie I Brown; Stephan A Grupp
Journal:  Blood       Date:  2005-09-29       Impact factor: 22.113

4.  Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells.

Authors:  Ghulam J Mufti; Dominique Bonnet; Syed A Mian; Ander Abarrategi; Kar Lok Kong; Kevin Rouault-Pierre; Henry Wood; Caroline A Oedekoven; Alexander E Smith; Antoniana Batsivari; Linda Ariza-McNaughton; Peter Johnson; Thomas Snoeks
Journal:  Blood Cancer Discov       Date:  2020-12-23

5.  Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.

Authors:  Amy L Samuels; Violet K Peeva; Rachael A Papa; Marin J Firth; Richard W Francis; Alex H Beesley; Richard B Lock; Ursula R Kees
Journal:  BMC Genomics       Date:  2010-04-21       Impact factor: 3.969

6.  Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.

Authors:  Jingchuan Zhang; Dongxian Jiang; Xiaojing Li; Jing Lv; Liang Xie; Li Zheng; Paul R Gavine; Qin Hu; Yuan Shi; Lijie Tan; Di Ge; Songtao Xu; Leon Li; Lifang Zhu; Yingyong Hou; Qun Wang
Journal:  Lab Invest       Date:  2014-07-07       Impact factor: 5.662

7.  Patient-derived xenografts recapitulate molecular features of human uveal melanomas.

Authors:  Cécile Laurent; David Gentien; Sophie Piperno-Neumann; Fariba Némati; André Nicolas; Bruno Tesson; Laurence Desjardins; Pascale Mariani; Audrey Rapinat; Xavier Sastre-Garau; Jérôme Couturier; Philippe Hupé; Leanne de Koning; Thierry Dubois; Sergio Roman-Roman; Marc-Henri Stern; Emmanuel Barillot; J William Harbour; Simon Saule; Didier Decaudin
Journal:  Mol Oncol       Date:  2013-02-26       Impact factor: 6.603

Review 8.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

9.  Rapid engraftment of human ALL in NOD/SCID mice involves deficient apoptosis signaling.

Authors:  M Queudeville; F Seyfried; S M Eckhoff; L Trentin; S Ulrich; M Schirmer; K-M Debatin; L H Meyer
Journal:  Cell Death Dis       Date:  2012-08-09       Impact factor: 8.469

10.  Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice.

Authors:  Susan J Zunino; David H Storms; John W Newman; Theresa L Pedersen; Carl L Keen; Jonathan M Ducore
Journal:  Int J Oncol       Date:  2012-10-04       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.